Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid

Area of Science:

• Pharmacology
• Molecular Biology
• Hematology

Background:

• Histone deacetylase (HDAC) inhibitors can induce fetal hemoglobin (HbF), but many lack in vivo efficacy.
• p38 mitogen-activated protein kinase (MAPK) signaling is implicated in gamma-globin promoter activation by HDAC inhibitors.

Purpose of the Study:

• To investigate scriptaid, a novel HDAC inhibitor, for its ability to induce gamma-globin expression through p38 MAPK signaling.
• To evaluate the in vivo efficacy of scriptaid in a relevant animal model for potential sickle cell disease treatment.

Main Methods:

• Assessed scriptaid's effect on gamma-globin induction in K562 cells and human erythroid progenitors.
• Utilized the p38-selective inhibitor SB203580 to confirm the role of p38 MAPK signaling.
• Administered scriptaid to beta-YAC transgenic mice to evaluate in vivo induction of gamma-globin mRNA and reticulocytosis.

Main Results:

• Scriptaid successfully induced gamma-globin in K562 cells and human erythroid progenitors.
• The p38 inhibitor SB203580 abolished scriptaid-induced HbF production, confirming pathway involvement.
• In vivo studies in beta-YAC mice showed scriptaid (1 mg/kg/day) significantly increased gamma-globin mRNA by 1.8-fold and induced reticulocytosis.

Conclusions:

• Scriptaid is a potent inducer of gamma-globin expression, acting via p38 MAPK signaling.
• Scriptaid demonstrates in vivo efficacy in a mouse model, suggesting potential as a therapeutic agent for sickle cell disease.